Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Adverum Biotechnologies (ADVM)

Adverum Biotechnologies Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ADVM
DateTimeSourceHeadlineSymbolCompany
11/06/202421:19Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ADVMAdverum Biotechnologies Inc
11/06/202421:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
11/06/202413:00GlobeNewswire Inc.Adverum Biotechnologies Announces Appointments of Dr. Rabia Gurses Ozden as Chief Medical Officer and Dr. Szilárd Kiss as a Member of the Board of DirectorsNASDAQ:ADVMAdverum Biotechnologies Inc
28/05/202419:00Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202421:13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202421:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
09/05/202421:05GlobeNewswire Inc.Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline HighlightsNASDAQ:ADVMAdverum Biotechnologies Inc
03/05/202413:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in Upcoming May Investor ConferencesNASDAQ:ADVMAdverum Biotechnologies Inc
25/04/202421:05GlobeNewswire Inc.Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific MeetingNASDAQ:ADVMAdverum Biotechnologies Inc
18/03/202420:05GlobeNewswire Inc.Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate UpdatesNASDAQ:ADVMAdverum Biotechnologies Inc
04/03/202421:40Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ADVMAdverum Biotechnologies Inc
28/02/202421:05GlobeNewswire Inc.Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
22/02/202420:47Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
21/02/202420:39Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ADVMAdverum Biotechnologies Inc
15/02/202421:17Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
15/02/202401:26Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ADVMAdverum Biotechnologies Inc
14/02/202421:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
14/02/202421:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
14/02/202421:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
14/02/202421:05Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ADVMAdverum Biotechnologies Inc
12/02/202413:00GlobeNewswire Inc.Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ADVMAdverum Biotechnologies Inc
09/02/202422:50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ADVMAdverum Biotechnologies Inc
09/02/202416:41Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ADVMAdverum Biotechnologies Inc
08/02/202413:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
08/02/202412:00GlobeNewswire Inc.Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMDNASDAQ:ADVMAdverum Biotechnologies Inc
06/02/202421:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
05/02/202422:03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ADVMAdverum Biotechnologies Inc
05/02/202412:45GlobeNewswire Inc.Adverum Biotechnologies Announces $127.5 Million Private Placement FinancingNASDAQ:ADVMAdverum Biotechnologies Inc
01/02/202422:30GlobeNewswire Inc.Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024NASDAQ:ADVMAdverum Biotechnologies Inc
29/01/202413:00GlobeNewswire Inc.Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific OfficerNASDAQ:ADVMAdverum Biotechnologies Inc
 Showing the most relevant articles for your search:NASDAQ:ADVM

Your Recent History